RhumbLine Advisers’s MiNK Therapeutics INKT Stock Holding History

RhumbLine Advisers’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5	Closed	-$43	–	4377
2024 Q1	$43	Buy	+5	New	+$46	﹤0.01%	4240

Other funds holding INKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's INKT Position: Q2 2024 in Review

RhumbLine Advisers sold out of MiNK Therapeutics (INKT) in Q2 2024, closing a stake of 5 shares — an estimated $43 sold.

RhumbLine Advisers first reported a position in INKT in Q1 2024 and held it in 1 quarter. The position peaked at $43 in Q1 2024. 29 funds tracked by Wall St. Rank hold INKT as of Q2 2024.

RhumbLine Advisers reported no remaining MiNK Therapeutics position as of Q2 2024 after selling out during the quarter.
RhumbLine Advisers sold 5 MiNK Therapeutics shares in Q2 2024, an estimated $43.
RhumbLine Advisers first reported a position in MiNK Therapeutics in Q1 2024 and held it in 1 quarter.
RhumbLine Advisers's MiNK Therapeutics position peaked at $43 in Q1 2024.
29 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2024.

Based on RhumbLine Advisers's 13F filing for Q2 2024, filed 1 Aug 2024.